Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GPRE
- Development stage
- Preclinical
- Modality
- Recombinant Proteins and Enzymes
01
Overview
GPRE refers to ribosomal protein factors extracted from MPC-11 cells using a high KCl procedure. These factors have been studied for their effects on acute myeloid leukemia (AML) blast cells. GPRE has been shown to prevent chromatin condensation and fragmentation of blast cell nuclei, increase the fraction of phagocytosing blast cells, and modulate the expression of surface antigens like CD11b, CD32, CD35, and CD11c. Its effects are thought to be mediated by ribosomal proteins that regulate translation and modulate the subcellular distribution of mRNA species, potentially inhibiting apoptosis.
- Other names
- ribosome protein factors
02
Targets
Ribosomal protein (Ribosomal protein family)
Beyond the preview
Go deeper on GPRE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GPRE.